Why Abbott Laboratories Stock Tumbled on Thursday

Abbott Laboratories posted Q1 sales of just under $11.2B, up nearly 8% year over year, with adjusted EPS of $1.15 roughly in line with consensus. The stock fell 6% after the company cut full-year 2026 adjusted EPS guidance to $5.38-$5.58 from $5.55-$5.80, citing dilution from the Exact Sciences acquisition. Full-year comparable sales are still projected to rise 6.5% to 7.5%.

Analysis

The market is treating this as an earnings miss, but the real issue is a valuation reset from lower forward earnings power, not a deterioration in core demand. That matters because ABT’s device franchise is still compounding and the guide cut appears largely mechanical from acquisition-related dilution, which usually creates a cleaner entry point than an operating slowdown. In other words, the selloff likely reflects near-term multiple compression more than a change in terminal earnings quality.

Second-order, the Exact Sciences close may actually improve Abbott’s strategic positioning in diagnostics and oncology-adjacent workflows, but the P&L timing masks that optionality. The near-term loser is the stock, while peers with cleaner growth profiles may see a relative bid as investors rotate toward less headline-risk healthcare names. If management can show even modest synergy capture or a faster-than-expected contribution ramp over the next 2-3 quarters, the current guide reset becomes a classic “one-time” event.

The key catalyst window is the next 6-12 weeks: any stabilization in reported EPS expectations, plus evidence that medical devices can sustain low-double-digit growth, should re-rate the shares. The downside tail is that the market starts underwriting a pattern of acquisition-driven dilution with little offsetting accretion, which would cap the multiple for several quarters. Consensus is likely over-penalizing the guide cut because it is extrapolating dilution linearly without assigning enough value to recurring device momentum and post-close operating leverage.

Key Decisions for Investors

• Buy ABT on weakness over the next 1-2 sessions; target a 3-6 month holding period with 15-20% upside if the market normalizes the guidance cut as non-recurring dilution.
• Use a call spread in ABT (3-6 month tenor) rather than stock if you want defined risk; the setup is favorable if implied volatility stays elevated after the post-earnings move.
• Pair trade: long ABT / short a healthcare name with weaker organic growth and no acquisition catalyst over the next quarter; this isolates the valuation reset while keeping sector beta neutral.
• If ABT fails to reclaim pre-earnings levels within 2-3 weeks, reduce exposure by 30-50%; the thesis depends on the market accepting that the guide cut is transitory, not structural.